# IBRX-042 In Participants With HPV-Associated Tumors

> **NCT05976828** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **ImmunityBio, Inc.** · enrollment: 12 (estimated)

## Conditions studied

- HPV-Related Carcinoma

## Interventions

- **DRUG:** IBRX-042

## Key facts

- **NCT ID:** NCT05976828
- **Lead sponsor:** ImmunityBio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-06-14
- **Primary completion:** 2027-09-02
- **Final completion:** 2033-08-14
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05976828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05976828, "IBRX-042 In Participants With HPV-Associated Tumors". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05976828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*